{"nctId":"NCT00516737","briefTitle":"Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","startDateStruct":{"date":"2007-10-03","type":"ACTUAL"},"conditions":["Migraine"],"count":207,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: rizatriptan benzoate"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"Comparator: rizatriptan benzoate","otherNames":["MK0462"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Greater than one year history of migraine\n* Attacks typically mild when they begin and progress to moderate or severe\n* Experience 1-4 migraine attacks per month\n\nExclusion Criteria:\n\n* More than 15 headache days per month\n* Heart disease\n* Uncontrolled high blood pressure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Are Pain Free at 2 Hours Post-Dose","description":"Pain severity was rated by the participants in a paper diary. Pain severity rating scale: 0 (no pain), 1 (mild), 2 (moderate), or 3 (severe). Pain free = rating of 0 (no pain) at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With 24-Hour Sustained Pain Freedom","description":"24-hour sustained pain freedom (defined as pain freedom from 2 to 24 hours post-dose and no use of rescue medication). Participants assessed pain severity and use of rescue medication on a paper diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With no Rescue Use up to 24 Hours Post-Dose","description":"Participants recorded use of any rescue medication up to 24 hours after dosing with study medication on a paper diary.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absence of Photophobia at 2 Hours Post-dose","description":"Absence or presence of photophobia was recorded by the participants on a paper diary. Absence is defined as no photophobia at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absence of Phonophobia at 2 Hours Post-dose","description":"Absence or presence of phonophobia was recorded by the participants on a paper diary. Absence is defined as no phonophobia at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absence of Nausea at 2 Hours Post-dose","description":"Absence or presence of nausea was recorded by the participants on a paper diary. Absence is defined as no nausea at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Absence of Functional Disability at 2 Hours Post-Dose","description":"Level of functional disability was assessed on a paper diary by the participants.\n\nLevel of functional disability was rated as: normal, mildly impaired, severely impaired or unable to do activities, requires bed rest. Absence of functional disability defined as a rating of normal at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":92},"commonTop":["Dizziness","Hyperchlorhydria","Nausea","Fatigue","Feeling cold"]}}}